CompletedPhase 2NCT00712582

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Intervention
Etoposide, carboplatin, ifosfamide(drug)
Enrollment
96 target
Eligibility
18-65 years · All sexes
Timeline
20082021

Study locations (1)

Collaborators

Genentech, Inc. · Columbia University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00712582 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials